title: Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
abstract: The retrovirus SL3 induces T-cell lymphomas in mice. The transcriptional enhancer in the long terminal repeat (LTR) of SL3 contains two 72-bp repeats. Each repeat contains a binding site for the transcription factor CBF (also called AML1). The CBF binding sites are called core elements. SAA is a mutant that is identical to SL3 except for the presence of a single-base-pair substitution in each of the two core elements. This mutation significantly attenuates viral lymphomagenicity. Most lymphomas that occur in SAA-infected mice contain proviruses with reversions or second-site suppressor mutations within the core element. We examined the selective pressures that might account for the predominance of the reversions and suppressor mutations in tumor proviruses by analyzing when proviruses with altered core sequences became abundant during the course of lymphomagenesis. Altered core sequences were easily detected in thymus DNAs by 4 to 6 weeks after SAA infection of mice, well before lymphomas were grossly evident. This result is consistent with the hypothesis that viruses with the core sequence alterations emerged because they replicated more effectively in mice than SAA. The number of 72-bp tandem, repeats in the viral LTR was found to vary, presumably as a consequence of reverse transcriptase slippage during polymerization. Proviruses with two repeats predominated in the thymuses of SAA- and SL3-infected mice before lymphomas developed, although LTRs with one or three repeats were also present. This suggested that two was the optimal number of 72-bp repeats for viral replication. However, in lymphomas, proviruses with three or four repeats usually predominated. This suggested that a late step in the process of lymphomagenesis led to the abundance of proviruses with additional repeats. We hypothesize that proviruses with additional 72-bp repeats endowed the cells containing them with a selective growth advantage.
authors.affiliation: Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Martiney
authors.forename: K
authors.initials: K
authors.lastname: Rulli
authors.forename: R
authors.initials: R
authors.lastname: Beaty
authors.forename: L S
authors.initials: LS
authors.lastname: Levy
authors.forename: J
authors.initials: J
authors.lastname: Lenz
mesh_terms: D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D050676:Core Binding Factor Alpha 2 Subunit; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D004742:Enhancer Elements, Genetic; D009052:Leukemia Virus, Murine / Q000235:genetics*; D007942:Leukemia, Experimental / Q000821:virology*; D016399:Lymphoma, T-Cell / Q000821:virology*; D051379:Mice; D008806:Mice, Inbred AKR; D008969:Molecular Sequence Data; D009154:Mutation; D011518:Proto-Oncogene Proteins; D011533:Proviruses / Q000235:genetics; D012091:Repetitive Sequences, Nucleic Acid; D012192:Retroviridae Infections / Q000821:virology*; D013489:Suppression, Genetic; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism*; D014412:Tumor Virus Infections / Q000821:virology*
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; C493726:Runx1 protein, mouse; D014157:Transcription Factors